The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. - Archive ouverte HAL Access content directly
Journal Articles Radiat Oncol Year : 2006

The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications.

(1) , (1) , (2) , (1)
1
2

Abstract

Epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors. Its stimulation by endogenous ligands, EGF or transforming growth factor-alpha (TGF-alpha) results in activation of intracellular tyrosine kinase, therefore, cell cycle progression. High levels of EGFR expression are correlated with poor prognosis and resistance to radiation therapy in a variety of cancers, mostly in squamous-cell carcinoma of the head and neck (SCCHN). Blocking the EGFR by a monoclonal antibody results in inhibition of the stimulation of the receptor, therefore, in inhibition of cell proliferation, enhanced apoptosis, and reduced angiogenesis, invasiveness and metastases. The EGFR is a prime target for new anticancer therapy in SCCHN, and other agents in development include small molecular tyrosine kinase inhibitors and antisense therapies.
Fichier principal
Vignette du fichier
1748-717X-1-11.pdf (178.23 Ko) Télécharger le fichier
Loading...

Dates and versions

inserm-00090010 , version 1 (25-08-2006)

Identifiers

Cite

Michel Zimmermann, Abderrahim Zouhair, David Azria, Mahmut Ozsahin. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications.. Radiat Oncol, 2006, 1, pp.11. ⟨10.1186/1748-717X-1-11⟩. ⟨inserm-00090010⟩
208 View
292 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More